Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
H Zhou, L Zhu, J Song, G Wang, P Li, W Li, P Luo… - Molecular cancer, 2022 - Springer
Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …
cancer. However, existing biomarkers do not reliably predict treatment response across …
Circulating tumor DNA and liquid biopsy in oncology
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a
negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD …
negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD …
[HTML][HTML] ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …
Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …
thousands of mutations most frequently located in monomorphic microsatellites and are …
Life and death of circulating cell-free DNA
A Kustanovich, R Schwartz, T Peretz… - Cancer biology & …, 2019 - Taylor & Francis
Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …
[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management
AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
[HTML][HTML] Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, S Kato… - Annals of …, 2019 - Elsevier
Novel patterns of response and progression to immunotherapy have been reported that are
not observed with conventional cytotoxic or targeted anticancer treatments. A major …
not observed with conventional cytotoxic or targeted anticancer treatments. A major …